Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(2.21) per share which beat the analyst consensus estimate of $(2.28) by 3.07 percent. This is a 4.74 percent decrease over losses of $(2.11) per share from the same period last year. The company reported quarterly sales of $2.830 million which beat the analyst consensus estimate of $500.000 thousand by 466.00 percent. This is a 809.97 percent increase over sales of $311.000 thousand the same period last year.